Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors : A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
© 2020 American Cancer Society..
BACKGROUND: Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Addition of antithymocyte globulin (ATG) or post-transplantation cyclophosphamide (PTCY) to standard immunosuppressive agents reduces GVHD in different donor settings.
METHODS: We compared the outcomes of adults with acute myeloid leukemia undergoing allo-HSCT from HLA-identical sibling donors after the use of PTCY (n = 197) or ATG (n = 1913).
RESULTS: Patients in the PTCY group were younger than those in the ATG group (median age, 47 vs 54 years; P < .01). Peripheral blood was the most frequently used stem cell source, being significantly more frequent in the ATG group than in the PTCY group (95% vs 70% P < .01). The conditioning regimen was more frequently myeloablative in the PTCY group than in the ATG group (59% vs 48%; P < .01). Time to neutrophil engraftment was shorter in the ATG group than in the PTCY group (17 vs 20 days; P < .01). No differences were observed according to the other transplantation outcomes, except for chronic GVHD of all grades and extensive chronic GVHD at 2 years, which were significantly lower in the ATG group compared with the PTCY group (P < .02).
CONCLUSION: PTCY is feasible in an HLA-identical sibling setting, and despite similar outcomes, ATG may be associated with lower incidence of chronic GVHD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:127 |
|---|---|
| Enthalten in: |
Cancer - 127(2021), 2 vom: 15. Jan., Seite 209-218 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Battipaglia, Giorgia [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.08.2021 Date Revised 27.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncr.33255 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316877123 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316877123 | ||
| 003 | DE-627 | ||
| 005 | 20231225162030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.33255 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM316877123 | ||
| 035 | |a (NLM)33119152 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Battipaglia, Giorgia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors |b A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.08.2021 | ||
| 500 | |a Date Revised 27.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 American Cancer Society. | ||
| 520 | |a BACKGROUND: Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Addition of antithymocyte globulin (ATG) or post-transplantation cyclophosphamide (PTCY) to standard immunosuppressive agents reduces GVHD in different donor settings | ||
| 520 | |a METHODS: We compared the outcomes of adults with acute myeloid leukemia undergoing allo-HSCT from HLA-identical sibling donors after the use of PTCY (n = 197) or ATG (n = 1913) | ||
| 520 | |a RESULTS: Patients in the PTCY group were younger than those in the ATG group (median age, 47 vs 54 years; P < .01). Peripheral blood was the most frequently used stem cell source, being significantly more frequent in the ATG group than in the PTCY group (95% vs 70% P < .01). The conditioning regimen was more frequently myeloablative in the PTCY group than in the ATG group (59% vs 48%; P < .01). Time to neutrophil engraftment was shorter in the ATG group than in the PTCY group (17 vs 20 days; P < .01). No differences were observed according to the other transplantation outcomes, except for chronic GVHD of all grades and extensive chronic GVHD at 2 years, which were significantly lower in the ATG group compared with the PTCY group (P < .02) | ||
| 520 | |a CONCLUSION: PTCY is feasible in an HLA-identical sibling setting, and despite similar outcomes, ATG may be associated with lower incidence of chronic GVHD | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute myeloid leukemia | |
| 650 | 4 | |a allogeneic hematopoietic transplantation | |
| 650 | 4 | |a antithymocyte globulin | |
| 650 | 4 | |a graft-versus-host disease | |
| 650 | 4 | |a post-transplantation cyclophosphamide | |
| 650 | 7 | |a Antilymphocyte Serum |2 NLM | |
| 650 | 7 | |a HLA Antigens |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 700 | 1 | |a Labopin, Myriam |e verfasserin |4 aut | |
| 700 | 1 | |a Hamladji, Rose-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Blaise, Didier |e verfasserin |4 aut | |
| 700 | 1 | |a Chevallier, Patrice |e verfasserin |4 aut | |
| 700 | 1 | |a Brissot, Eolia |e verfasserin |4 aut | |
| 700 | 1 | |a Gerbitz, Armin |e verfasserin |4 aut | |
| 700 | 1 | |a Socié, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Afanasyev, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a Ciceri, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Meijer, Ellen |e verfasserin |4 aut | |
| 700 | 1 | |a Koc, Yener |e verfasserin |4 aut | |
| 700 | 1 | |a Cornelissen, Jan J |e verfasserin |4 aut | |
| 700 | 1 | |a Huynh, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Ozdogu, Hakan |e verfasserin |4 aut | |
| 700 | 1 | |a Maertens, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Franciane |e verfasserin |4 aut | |
| 700 | 1 | |a Labussière-Wallet, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Ruggeri, Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a Aljurf, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Bazarbachi, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Savani, Bipin |e verfasserin |4 aut | |
| 700 | 1 | |a Nagler, Arnon |e verfasserin |4 aut | |
| 700 | 1 | |a Mohty, Mohamad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d 1948 |g 127(2021), 2 vom: 15. Jan., Seite 209-218 |w (DE-627)NLM000028649 |x 1097-0142 |7 nnns |
| 773 | 1 | 8 | |g volume:127 |g year:2021 |g number:2 |g day:15 |g month:01 |g pages:209-218 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncr.33255 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 127 |j 2021 |e 2 |b 15 |c 01 |h 209-218 | ||